Scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable.
The quest for a vaccine against rhinoviruses may have seemed quixotic, because there are more than 100 varieties circulating around the world. Even so, the immune system can handle the challenge, researchers from Emory University School of Medicine and Children’s Healthcare of Atlanta say.
Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, the researchers report in Nature Communications. The paper was also posted on Biorxiv before publication.
“We think that creating a vaccine for the common cold can be reduced to technical challenges related to manufacturing,” says Martin Moore, PhD, associate professor of pediatrics at Emory University School of Medicine.
Rhinoviruses are the most common cause of the common cold; other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although they come in many varieties, rhinoviruses do not drift to the same degree that influenza viruses do, Moore says.
Researchers showed in the 1960s that it was possible to vaccinate people against one variety of rhinovirus and prevent them from getting sick when challenged with samples of the same virus. The trouble was the sheer diversity of rhinoviruses – or that’s how it appeared at the time.
“It’s surprising that nobody tried such a simple solution over the last 50 years. We just took 50 types of rhinovirus and mixed them together into our vaccine, and made sure we had enough of each one,” Moore says. “If we make a vaccine with 50 or 100 variants, it’s the same amount of total protein in a single dose of vaccine. The variants are like a bunch of slightly different Christmas ornaments, not really like 50 totally different vaccines mixed.”
A mixture of 25 types of inactivated rhinovirus can stimulate neutralizing antibodies against all 25 in mice, and a mixture of 50 types can do the same thing in rhesus macaques. In this paper, antibodies generated in response to the vaccine were tested for their ability to prevent the virus from infecting human cells in culture. However, the vaccines were not tested for their ability to stop animals from getting sick.
“There are no good animal models of rhinovirus replication,” Moore says. “The next step would be human challenge models with volunteers, which are feasible because the virus is not very pathogenic.”
Emory has optioned the vaccine technology to a startup company, Meissa Vaccines, Inc., which is pursuing a product development plan with support from the National Institute of Allergy and Infectious Diseases’ vaccine manufacturing services.
Learn more: Vaccine vs many common cold viruses achievable
The Latest on: Vaccine against rhinoviruses
via Google News
The Latest on: Vaccine against rhinoviruses
- New assay rapidly tests SARS-CoV-2 neutralization and screens antiviralson June 23, 2020 at 5:00 pm
“Thus, the assay can be readily deployed for large-scale vaccine evaluation and neutralizing ... including ones known to work against HIV, hepatitis C virus, and human rhinovirus. Of 40 compounds ...
- Inside the Coronaviruson June 23, 2020 at 9:23 am
For all the mysteries that remain about the novel coronavirus and the COVID-19 disease it causes, scientists have generated an incredible amount of fine-grained knowledge in a surprisingly short time.
- The Race to Develop a Covid Vaccineon June 22, 2020 at 5:20 pm
Judging from comments I’ve heard and read, many Americans expect that a vaccine against Covid-19 will soon end the need for masks and social distancing and enable us to resume our pre-Covid lives.
- Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containerson June 19, 2020 at 4:49 pm
The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that ... pharmaceutical companies in ...
- Why we need to learn to live with COVID-19on June 19, 2020 at 8:20 am
But for every disease caused by a virus, such as measles, or even mumps and rubella, where a vaccine was found ... including common ones like the rhinovirus, which leads to the common cold ...
- A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitroon June 16, 2020 at 2:13 am
Despite these early successes, whether or not viable cross-reactive targets for cross-protective vaccines exist remains an open question. To further identify potential future vaccination target ...
- Nine simple ways to boost your immunityon June 14, 2020 at 5:00 pm
The immune system is made up of organs, cells, tissues and processes that fight against germs and toxins ... Another study of 152 people infected with a rhinovirus found that those who ...
- Flu vaccine reduces influenza risk with no effect on coronaviruseson June 5, 2020 at 3:07 am
Please provide your email address to receive an email when new articles are posted on . To assess this, Skowronski and colleagues retrospectively applied test-negative design (TND) analysis to ...
- Austin woman joins COVID-19 vaccine trial after family member dies of viruson May 27, 2020 at 6:41 pm
A little more than a year ago, she participated in a trial for a combination pertussis and rhinovirus vaccine through Benchmark ... lacks efficacy against coronavirus Significantly more Americans ...
via Bing News